Clinical Trial Update: A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of Gefapixant (AF-219/MK-7264) in osteoarthritis of the knee has been completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Osteoarthritis of the Knee | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01